Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

A Low-Cost HPV Immunochromatographic Assay to Detect High-Grade Cervical Intraepithelial Neoplasia.

Mariano VS, Lorenzi AT, Scapulatempo-Neto C, Stein MD, Resende JC, Antoniazzi M, Villa LL, Levi JE, Longatto-Filho A, Fregnani JH.

PLoS One. 2016 Oct 20;11(10):e0164892. doi: 10.1371/journal.pone.0164892. eCollection 2016.

2.

Cervical and anal HPV infection: cytological and histological abnormalities in HIV-infected women in Thailand.

Ramautarsing RA, Phanuphak N, Chaithongwongwatthana S, Wit FW, Teeratakulpisarn N, Pankam T, Rodbamrung P, Wijgert JH, Lange JM, Phanuphak P, Sahasrabuddhe VV, Kerr S, Ananworanich J.

J Virus Erad. 2015 Apr 1;1(2):96-102.

3.

The road ahead for cervical cancer prevention and control.

Tota JE, Ramana-Kumar AV, El-Khatib Z, Franco EL.

Curr Oncol. 2014 Apr;21(2):e255-64. doi: 10.3747/co.21.1720.

4.

Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer.

Tornesello ML, Buonaguro L, Giorgi-Rossi P, Buonaguro FM.

Biomed Res Int. 2013;2013:519619. doi: 10.1155/2013/519619. Epub 2013 Dec 9. Review.

5.

Lower cost strategies for triage of human papillomavirus DNA-positive women.

Qiao YL, Jeronimo J, Zhao FH, Schweizer J, Chen W, Valdez M, Lu P, Zhang X, Kang LN, Bansil P, Paul P, Mahoney C, Berard-Bergery M, Bai P, Peck R, Li J, Chen F, Stoler MH, Castle PE.

Int J Cancer. 2014 Jun 15;134(12):2891-901. doi: 10.1002/ijc.28616. Epub 2013 Dec 3.

6.

HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease.

Luhn P, Wentzensen N.

Curr Obstet Gynecol Rep. 2013 Jun 1;2(2):76-85.

7.

Claspin as a biomarker of human papillomavirus-related high grade lesions of uterine cervix.

Benevolo M, Musio A, Vocaturo A, DonĂ  MG, Rollo F, Terrenato I, Carosi M, Pescarmona E, Vocaturo G, Mottolese M.

J Transl Med. 2012 Jun 25;10:132. doi: 10.1186/1479-5876-10-132.

8.

Cervical cancers require the continuous expression of the human papillomavirus type 16 E7 oncoprotein even in the presence of the viral E6 oncoprotein.

Jabbar SF, Park S, Schweizer J, Berard-Bergery M, Pitot HC, Lee D, Lambert PF.

Cancer Res. 2012 Aug 15;72(16):4008-16. doi: 10.1158/0008-5472.CAN-11-3085. Epub 2012 Jun 13.

9.

New technologies for cervical cancer screening.

Brown AJ, Trimble CL.

Best Pract Res Clin Obstet Gynaecol. 2012 Apr;26(2):233-42. doi: 10.1016/j.bpobgyn.2011.11.001. Epub 2011 Nov 25. Review.

10.

Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts.

Sahasrabuddhe VV, Luhn P, Wentzensen N.

Future Microbiol. 2011 Sep;6(9):1083-98. doi: 10.2217/fmb.11.87. Review.

12.

Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.

Benevolo M, Vocaturo A, Caraceni D, French D, Rosini S, Zappacosta R, Terrenato I, Ciccocioppo L, Frega A, Giorgi Rossi P.

J Clin Microbiol. 2011 Jul;49(7):2643-50. doi: 10.1128/JCM.02570-10. Epub 2011 Apr 27.

13.

Looking ahead: a case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy.

Gravitt PE, Belinson JL, Salmeron J, Shah KV.

Int J Cancer. 2011 Aug 1;129(3):517-27. doi: 10.1002/ijc.25974. Review.

Supplemental Content

Support Center